SANJAY MATHEW to Receptors, Opioid, kappa
This is a "connection" page, showing publications SANJAY MATHEW has written about Receptors, Opioid, kappa.
Connection Strength
1.112
-
Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):267-276.
Score: 0.945
-
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
Score: 0.167